Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Azacitidine is First Drug to Prolong Survival in High-Risk Myelodysplastic Syndromes
Link ID 1575
Title Azacitidine is First Drug to Prolong Survival in High-Risk Myelodysplastic Syndromes
Url http://www.medscape.com/viewarticle/567277?src=rss
Description For the first time, a significant prolongation of survival has been seen in this disorder, leading to calls for azacitidine to be offered to all high-risk patients. Medscape Medical News
Category Articles > Hematology-Oncology
Keywords
Date Dec 14, 2007
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Hematology-Oncology
1. The Management of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances in Diagnosis and Treatment an
  Outline issues and complications related to paroxysmal nocturnal hemoglobinuria (PNH), and review current and emerging treatment regimens for patients with PNH.
Category:   Articles > Hematology-Oncology


2. Management of Nerve Sheath Tumors Arising in the Sympathetic Chain
  Extradural schwannomas are uncommon and can present management challenges. Three case studies are reviewed to detail specific management practices for cervical, thoracic, and lumbar lesions.
Cancer Control: Journal of the Moffitt Cancer Center
Category:   Articles > Hematology-Oncology


3. Customizing Treatment for Advanced NSCLC: Histology Matters
  Recent studies have found that specific histologic subgroups of NSCLC respond more favorably to particular therapies. This expert column focuses on the role of histology in selecting NSCLC therapies and improving patient outcomes. Medscape Hematology-Oncology
Category:   Articles > Hematology-Oncology


4. Management of Opioid-Induced Side Effects
  How do you choose treatments for cancer-related opioid-induced side effects while considering the patient’s disease and quality of life issues?
Category:   Articles > Hematology-Oncology


5. Adjuvant Therapy for HER2-Positive Breast Cancer: An Expert Interview With Dr. Harold Burstein
  What do clinicians need to know in 2008? Dr. Harold Burstein brings readers up to date about trastuzumab-based regimens, selecting a chemotherapy backbone, and monitoring cardiac function.
Medscape Hematology-Oncology
Category:   Articles > Hematology-Oncology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS